WINLEVI

This brand name is authorized in United States. It is also authorized in Austria, Estonia, Lithuania, UK.

Active ingredients

The drug WINLEVI contains one active pharmaceutical ingredient (API):

1	Clascoterone UNII XN7MM8XG2M - CLASCOTERONE
	Clascoterone is an androgen receptor inhibitor. In vitro studies showed that it potently antagonizes the effects of androgens in primary human sebocytes to reduce sebum production and accumulation and inflammatory mediators which are known drivers of the acne pathogenesis.
	Read more about Clascoterone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
WINLEVI Cream	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D10AX06		D Dermatologicals → D10 Anti-acne preparations → D10A Anti-acne preparations for topical use → D10AX Other anti-acne preparations for topical use
Discover more medicines within D10AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3133404, 3133415, 3133426
LT	Valstybinė vaistų kontrolės tarnyba	1105079, 1105080, 1105081
US	FDA, National Drug Code	47335-994